具体来看，活动时间为11月18日至12月1日。报名条件为本次活动期间持有过"英诺特"股票的投资者且 个人交易账号可以在同花顺App登录。一等奖为iPhone 17 Pro Max（256GB）；二等奖为大疆DJI Mini 4K无人机；三等奖为居家检测产品。其中，三等奖居家检测产品为公司甲型流感病毒、乙型流感病 毒、新型冠状病毒(2019-nCoV)抗原检测试剂盒（乳胶法），同时适用于医疗机构专业人员使用及非专 业人士居家自测。 北京商报讯（记者 丁宁）11月17日晚间，英诺特（688253）发布公告称，公司为建立长效、多样的股 东回报机制，感谢广大股东长期以来对公司的关注和支持，现联合浙江核新同花顺网络信息股份有限公 司（以下简称"同花顺"）开展"上市公司股东节"股东回馈活动。 ...

每经AI快讯，11月17日，英诺特(688253.SH)公告称，为感谢股东支持，联合同花顺开展"上市公司股东 节"股东回馈活动。活动时间自2025年11月18日至12月1日。奖品包括iPhone17ProMax、大疆DJIMini4K 无人机及英诺特居家检测产品（甲型流感病毒、乙型流感病毒、新型冠状病毒抗原检测试剂盒）。参与 条件为活动期间持有英诺特股票且可在同花顺App登录的投资者。 ...

广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 中新网11月10日电 国家疾控局10日举行新闻发布会。会上，中国疾病预防控制中心病毒病所研究员王 大燕介绍，监测数据显示，往年开始进入流感流行季的时间一般都是在10—11月，个别年度也有9月份 开始，流行高峰的时间一般出现在12月中下旬和1月初。依托中国流感监测系统，疾控部门对各地流感 活动实时开展监测预警和风险评估，当前我国总体流感活动属于上升阶段，甲型H3N2亚型占比超过 95%，有少量甲型H1N1和乙型流感病毒同期流行。 中国疾控中心：目前全国流感总体处于中流行水平 王大燕表示，目前，全国流感总体处于中流行水平，各省份流行强度有所区别，有23个省份处于中流行 水平，其他省份处于低流行水平，大致来看，南方省份流感活动高于北方。本次流行季前期将以甲型 H3N2亚型为主流行，甲型H1N1和乙型流感病毒共同流行，不同型别和亚型在各地区的比例会有所不 同，仍为季节性流行水平，流行 ...

Core Viewpoint - The company, Shengxiang Biology, announced on October 31 that several of its nucleic acid testing kits for respiratory viruses have received medical device registration certificates from the National Medical Products Administration of China, indicating regulatory approval for these products [1] Product Approval - The approved products include nucleic acid testing kits for respiratory syncytial virus, influenza A and B viruses, adenovirus, and mycoplasma pneumoniae, all utilizing fluorescent PCR methods [1] - The approval of these products is expected to enhance the company's market presence and product offerings in the diagnostic sector [1] Future Performance Uncertainty - The future performance of these products will be influenced by multiple factors, including market expansion efforts, brand influence, and actual market demand [1] - The company has indicated that the sales and profit contributions from these products remain uncertain, making it difficult to predict their specific impact on future performance [1]

Core Viewpoint - Shengxiang Bio (688289.SH) has recently received medical device registration certificates from the National Medical Products Administration for four products, enhancing its respiratory pathogen detection capabilities [1] Product Registration - The four products include nucleic acid test kits for respiratory syncytial virus, influenza A virus, influenza B virus, adenovirus, and mycoplasma pneumoniae, all utilizing fluorescent PCR technology [1] - These products are characterized by high sensitivity, high specificity, and ease of operation, allowing for accurate identification in as little as 30 minutes [1] Product Series Expansion - With this certification, the "Xiaolianjian" series has expanded to eight products, further enhancing Shengxiang's "6/3+X respiratory infection nucleic acid rapid detection" system [1] - This system enables unified sampling, amplification, and simultaneous detection of various common respiratory pathogens [1] Application and Flexibility - The product series covers common respiratory viruses, bacteria, fungi, atypical pathogens, and drug resistance genes, making it suitable for outpatient, emergency, and inpatient settings [1] - The products support flexible combinations based on clinical presentation, regional, and seasonal epidemic characteristics, effectively addressing complex situations such as co-circulation of multiple pathogens and mixed infections [1]

Core Viewpoint - Shengxiang Bio (688289.SH) has recently received medical device registration certificates from the National Medical Products Administration for four products, enhancing its capabilities in respiratory pathogen detection [1] Group 1: Product Details - The approved products include nucleic acid testing kits for respiratory syncytial virus, influenza A and B viruses, adenovirus, and mycoplasma pneumoniae, all utilizing fluorescent PCR methods [1] - These products enable unified sampling, amplification, and simultaneous detection of multiple common respiratory pathogens, supporting precise clinical medication and antibiotic management [1] Group 2: Market Impact - The future performance of these products post-approval is influenced by various factors, including market expansion efforts, brand influence, and actual market demand [1] - There is uncertainty regarding product sales and profit contributions due to these influencing factors [1]

Group 1 - The Ministry of Commerce plans to introduce several policy measures next month to expand service consumption, utilizing fiscal and financial tools to enhance service supply capacity and stimulate new service consumption growth [2][4] - The Shanghai Municipal Government has released implementation opinions to accelerate the renovation of urban villages, prioritizing areas with urgent public needs and safety concerns, and encouraging banks to provide loans for these projects [4] - The Jiangsu Provincial Government and the Ministry of Commerce have issued a development plan for the biopharmaceutical industry in the China (Jiangsu) Free Trade Zone, focusing on innovative drugs and enhancing medical service supply [5] Group 2 - NVIDIA has launched the Jetson Thor computing platform designed for robotics, which will serve as the "brain" for robotic systems in research and industrial applications, capable of running multiple generative AI models on edge devices [8][9] - Northern Rare Earth reported a significant increase in net profit for the first half of the year, with revenue reaching 18.866 billion yuan, a year-on-year growth of 45.24%, and net profit soaring by 1951.52% to 931 million yuan [11] - Tianshan Aluminum achieved a revenue of 15.328 billion yuan in the first half of the year, a year-on-year increase of 11.19%, while China Jushi reported a revenue of 9.109 billion yuan, up 17.70% [13] Group 3 - Shengxiang Bio received medical device registration certificates for two products, which utilize multiplex fluorescent PCR technology for high-sensitivity detection of respiratory pathogens [15] - Xinjie Electric plans to invest 800 million yuan in a new production project for intelligent control systems for robots, sourcing funds from its own capital and bank loans [17] - Kesi Technology has received a bid notification for a project with a total amount of 61.7584 million yuan [18]